Tarsadia

Tarsadia is a private investment firm that makes high-conviction investments in category-defining companies globally. With over $2 billion in assets under management, the firm has a history of seeking out and working with exceptional management teams across various industries. Their investment approach spans both private and public markets, combining the power of a permanent capital base with the scale of a best-in-class investment firm.

The firm's investment strategies include venture and growth equity, life sciences, and real estate. In venture and growth equity, Tarsadia partners with companies from Series A and beyond, writing checks ranging from $5 million to $75 million. They often lead investments but can also invest as part of a syndicate, focusing on founders addressing systemic problems in large end markets. In life sciences, Tarsadia backs passionate, driven teams with deep domain knowledge, investing in drug delivery technologies and preclinical and early clinical-stage assets within CNS, inflammation/immunology, oncology, and biosimilars. Their real estate strategy involves creatively identifying hidden value and executing with speed and certainty, having completed over $1 billion in hotel acquisitions and development.

Tarsadia's team comprises investors, operators, and entrepreneurs who value intellectual honesty and encourage debate. They work hard but strive to create an environment where it doesn't seem like hard work. The firm's diverse team brings a wealth of experience and expertise, supporting founders on growth, talent, and M&A/capital raising. Tarsadia's flexible mandate enables creative deal structures, including financing growth, recapitalizations, or acquisitions of significant competitors, allowing them to be supportive, engaged partners throughout the life cycle of their portfolio companies in private and public markets.